PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA USING RISPERIDONE AS AN ACTIVE CONTROL •To evaluate the efficacy of PF-02545920 in the treatment of acute exacerbation of schizophrenia during a 4-week double-blind treatment period using the Positive and Negative Syndrome Scale (PANSS) to...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study safety and effectiveness of a reduce to quit approach using varenicline versus placebo The primary objective is to compare the efficacy of varenicline to placebo for smoking cessation during the last 10 weeks of treatment in subjects who are not willing/able to make an abrupt quit attem...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME) Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with d...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

EFFECTS OF PREGABALIN ON SLEEP MAINTENANCE IN SUBJECTS WITH FIBROMYALGIA SYNDROME AND SLEEP MAINTENANCE DISTURBANCE: A RANDOMIZED PLACEBO-CONTROLLED 2-WAY CROSSOVER POLYSOMNOGRAPHY STUDY • To demonstrate the effect of pregabalin compared to placebo on sleep maintenance as measured by WASO obtained by PSG in patients with fibromyalgia and sleep maintenance disturbance.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 1, OPEN-LABEL STUDY OF LATANOPROST ACID PLASMA CONCENTRATIONS IN PEDIATRIC AND ADULT GLAUCOMA PATIENTS TREATED WITH LATANOPROST 0.005% To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 µg) in pediatric and adult subjects with glaucoma or ocular hyperten...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER Phase 1B: To assess the tolerability of PF-04691502 combined with letrozole in postmenopausal patients with ER positive, HER 2 negative advanced breast cancer. Phase 2: To compare the change in Ki-67...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER To demonstrate an improvement in progression-free survival (PFS) in patients with mCRC treated with sunitinib plus FOLFOX compared with bevacizumab plus FOLFOX in the first-line treatment setting.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIOUSLY TAKEN VARENICLINE The primary objective of this study is to compare the efficacy and safety of the re-treatment with varenicline with placebo for smoking cessation for the last 4 weeks of a 12 week treatment period (Co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune